Inspire presents additional Tiger-1 data

The USA's Inspire Pharmaceuticals presented additional data from its TIGER-1 Phase III trial of denufosol tetrasodium for the treatment of cystic fibrosis, at the North American Cystic Fibrosis Conference in Orlando, Florida.

The new data indicated that patients who continued to receive denufosol for an additional 24 weeks during the open-label extension experienced a progressive improvement in forced expiratory volume in one second. Those patients who received denufosol for 48 weeks during TIGER-1 experienced a mean change from baseline in FEV1 of 115ml, almost a two-and-a-half fold increase from the initial 48ml increase at the end of the 24-week placebo-controlled portion of the trial.